Torre LA, Bray F, Siegel RL, et al.Global cancer statistics, 2012. CA Cancer J Clin. 2015; 65(2):87–108.

Article  Google Scholar 

Edgren G, Adami HO, Weiderpass E, et al.A global assessment of the oesophageal adenocarcinoma epidemic. Gut. 2013; 62(10):1406–14.

Article  Google Scholar 

CRUK. Cancer Statistics for the UK. http://www.cancerresearchuk.org/health-professional/cancer-statistics. Accessed 19 Aug 2019.

Cunningham D, Allum WH, Stenning SP, et al.Perioperative chemotherapy versus surgery alone for resectable oesophagogastric cancer. N Engl J Med. 2006; 355(1):11–20.

CAS  Article  Google Scholar 

MRC. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet. 2002; 359(9319):1727–33.

Article  Google Scholar 

van Hagen P, Hulshof MC, van Lanschot JJ, et al.Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012; 366(22):2074–84.

CAS  Article  Google Scholar 

Cunningham D, Starling N, Rao S, et al.Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008; 358(1):36–46.

CAS  Article  Google Scholar 

Van Cutsem E, Moiseyenko VM, Tjulandin S, et al.Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol. 2006; 24(31):4991–7.

CAS  Article  Google Scholar 

Moehler M, Shitara K, Garrido M, Salman P, Shen L, Wyrwicz L, Yamaguchi K, Skoczylas T, Bragagnoli AC, Liu T, Schenker M. LBA6_PR Nivolumab (nivo) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC)/esophageal adenocarcinoma (EAC): First results of the CheckMate 649 study. Ann Oncol. 2020; 31:S1191.

Article  Google Scholar 

Bang YJ, Van Cutsem E, Feyereislova A, et al.Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010; 376(9742):687–97.

CAS  Article  Google Scholar 

Ford HE, Marshall A, Bridgewater JA, et al.Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. Lancet Oncol. 2014; 15(1):78–86.

CAS  Article  Google Scholar 

Kang JH, Lee SI, Lim DH, et al.Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J Clin Oncol. 2012; 30(13):1513–8.

CAS  Article  Google Scholar 

Fuchs CS, Tomasek J, Yong CJ, et al.Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2014; 383(9911):31–39.

CAS  Article  Google Scholar 

Wilke H, Muro K, Van Cutsem E, et al.Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 2014; 15(11):1224–35.

CAS  Article  Google Scholar 

Robert C, Schachter J, Long GV, et al.Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med. 2015; 372(26):2521–32.

CAS  Article  Google Scholar 

Larkin J, Chiarion-Sileni V, Gonzalez R, et al.Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med. 2015; 373(1):23–34.

Article  Google Scholar 

Brahmer J, Reckamp KL, Baas P, et al.Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med. 2015; 373(2):123–35.

CAS  Article  Google Scholar 

Rosenberg JE, Hoffman-Censits J, Powles T, et al.Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016; 387(10031):1909–20.

CAS  Article  Google Scholar 

Motzer RJ, Escudier B, McDermott DF, et al.Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015; 373(19):1803–13.

CAS  Article  Google Scholar 

Kang Y-K, Satoh T, Ryu M-H, et al.Nivolumab (ONO-4538/BMS-936558) as salvage treatment after second or later-line chemotherapy for advanced gastric or gastro-esophageal junction cancer (AGC): A double-blinded, randomized, phase III trial. J Clin Oncol. 2017; 35(4_suppl):2.

Article  Google Scholar 

Janjigian YY, Bendell J, Calvo E, et al.CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer. J Clin Oncol. 2018; 36(28):2836–44.

CAS  Article  Google Scholar 

Fuchs CS, Doi T, Jang RW, et al.Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Oesophagogastric Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial. JAMA Oncol. 2018; 4(5):e180013.

Article  Google Scholar 

Shitara K, Ozguroglu M, Bang YJ, et al.Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet. 2018; 392(10142):123–33.

CAS  Article  Google Scholar 

Tabernero J, Van Cutsem E, Bang Y, et al.LBA-002 Pembrolizumab with or without chemotherapy versus chemotherapy for first-line treatment of advanced gastric or oesophagogastric junction (G/GEJ) adenocarcinoma: The Phase 3 KEYNOTE-062 Study. Ann Oncol. 2019; 30(Supplement_4):mdz183.001.

Google Scholar 

Kim ST, Cristescu R, Bass AJ, et al.Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. Nat Med. 2018; 24(9):1449–58.

CAS  Article  Google Scholar 

Hochhauser D, Glynne-Jones R, Potter V, et al.A phase II study of temozolomide in patients with advanced aerodigestive tract and colorectal cancers and methylation of the O6-methylguanine-DNA methyltransferase promoter. Mol Cancer Ther. 2013; 12(5):809–18.

CAS  Article  Google Scholar 

Pietrantonio F, Perrone F, de Braud F, et al.Activity of temozolomide in patients with advanced chemorefractory colorectal cancer and MGMT promoter methylation. Ann Oncol. 2014; 25(2):404–8.

CAS  Article  Google Scholar 

Germano G, Lamba S, Rospo G, et al.Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth. Nature. 2017; 552(7683):116–20.

CAS  Article  Google Scholar 

Banissi C, Ghiringhelli F, Chen L, et al.Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model. Cancer Immunol Immunother. 2009; 58(10):1627–34.

CAS  Article  Google Scholar 

Ellsworth S, Balmanoukian A, Kos F, et al.Sustained CD4(+) T cell-driven lymphopenia without a compensatory IL-7/IL-15 response among high-grade glioma patients treated with radiation and temozolomide. Oncoimmunology. 2014; 3(1):e27357.

Article  Google Scholar 

Fadul CE, Fisher JL, Gui J, et al.Immune modulation effects of concomitant temozolomide and radiation therapy on peripheral blood mononuclear cells in patients with glioblastoma multiforme. Neuro Oncol. 2011; 13(4):393–400.

CAS  Article  Google Scholar 

Grossman SA, Ye X, Lesser G, et al.Immunosuppression in patients with high-grade gliomas treated with radiation and temozolomide. Clin Cancer Res. 2011; 17(16):5473–80.

CAS  Article  Google Scholar 

Karachi A, Yang C, Dastmalchi F, et al.Modulation of temozolomide dose differentially affects T-cell response to immune checkpoint inhibition. Neuro Oncol. 2019; 21(6):730–41.

CAS  Article  Google Scholar 

Ouyang M, White EE, Ren H, et al.Metronomic Doses of Temozolomide Enhance the Efficacy of Carbon Nanotube CpG Immunotherapy in an Invasive Glioma Model. PLoS ONE. 2016; 11(2):e0148139.

Article  Google Scholar 

Sampson JH, Aldape KD, Archer GE, et al.Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma. Neuro Oncol. 2011; 13(3):324–33.

CAS  Article  Google Scholar 

A’Hern RP. Sample size tables for exact single-stage phase II designs. Stat Med. 2001; 20(6):859–66.

Article  Google Scholar 

Clopper C, Pearson ES. The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika. 1934; 26(4):404–13.

Article  Google Scholar 

Lee LYW, Cazier J-B, Starkey T, et al.COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study. Lancet Oncol. 2020; 21(10):1309–16.

CAS  Article  Google Scholar 

Chan A-W, Tetzlaff JM, Altman DG, Laupacis A. Gøtzsche PC, Krleža-Jerić K, et al. SPIRIT 2013 Statement: Defining standard protocol items for clinical trials. Ann Intern Med. 2013; 158:200–7.

Article  Google Scholar